In one person with severe thyroid overactivity that didn't respond to standard medications, adding cholestyramine caused thyroid hormone levels to return to normal within a week. This finding is from the abstract summary - full study details were not available.
Claim Context
In a patient with Graves' disease resistant to methimazole, propranolol, and iodine, the addition of cholestyramine led to complete normalization of serum thyroid hormone levels within one week, suggesting a potential adjunctive role for bile acid sequestrants in refractory hyperthyroidism.
“Cholestyramine, a bile acid sequestrant, was then added, and a dramatic improvement was observed... thyroid hormone levels completely normalized after 1 week of additional treatment with cholestyramine.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether cholestyramine consistently leads to thyroid hormone normalization across multiple refractory Graves' disease cases, and whether this effect is reproducible and clinically meaningful compared to standard alternatives.
A systematic review and meta-analysis of all published case reports and small series of patients with Graves' disease refractory to antithyroid drugs, comparing thyroid hormone trajectories before and after cholestyramine addition, with standardized definitions of normalization, duration of treatment, and exclusion of confounding interventions.
Whether cholestyramine, when added to standard antithyroid therapy, causes a greater rate of thyroid hormone normalization compared to placebo in patients with confirmed refractory Graves' disease.
A double-blind, placebo-controlled trial of 50 adults aged 18–65 with confirmed Graves' disease and persistent hyperthyroidism despite ≥3 months of methimazole and beta-blockers, randomized to receive cholestyramine 4g three times daily or placebo for 4 weeks, with primary outcome being time to normalization of free T4 and TSH levels.
Whether the use of cholestyramine in refractory Graves' disease is associated with higher rates of euthyroidism over time compared to those who do not receive it, while adjusting for confounders like age, drug adherence, and disease severity.
A prospective cohort study following 100 patients with refractory Graves' disease treated with cholestyramine versus 100 matched controls without cholestyramine, tracking thyroid hormone levels monthly for 6 months, adjusting for baseline TSH, FT4, TRAb levels, and medication adherence.
That cholestyramine may be associated with rapid thyroid hormone normalization in select cases of refractory Graves' disease, serving as a signal for further investigation.
A detailed case report documenting thyroid hormone levels, medication history, and clinical symptoms before and after cholestyramine initiation in a single patient with confirmed refractory Graves' disease, including laboratory timing and exclusion of other interventions.